How might the MORPHO trial of gilteritinib impact clinical practice? 

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK, shared his insights with the AML Hub. We asked, How might the MORPHO trial of gilteritinib impact clinical practice
Firstly, Craddock provides an overview of the phase III MORPHO trial (NCT02997202), highlighting the impact of measurable residual disease status pre- or posttransplant on survival outcomes; then, he considers the implications on future trials assessing posttransplant maintenance therapies in other patient subgroups. Craddock concludes by emphasizing the need for more randomized trials to optimize transplant outcomes.